The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Abstract
Apoptosis-inducing ligand 2 (Apo2L, also called TRAIL), a member of the tumor necrosis factor (TNF) family, induces apoptosis in a variety of human tumor cell lines but not in normal cells [Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Immunity 3, 673-682; Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) J. Biol. Chem. 271, 12687-12690]. Here we describe the structure of Apo2L at 1.3 A resolution and use alanine-scanning mutagenesis to map the receptor contact regions. The structure reveals a homotrimeric protein that resembles TNF with receptor-binding epitopes at the interface between monomers. A zinc ion is buried at the trimer interface, coordinated by the single cysteine residue of each monomer. The zinc ion is required for maintaining the native structure and stability and, hence, the biological activity of Apo2L. This is the first example of metal-dependent oligomerization and function of a cytokine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,085
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationInduction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Self-citationOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity
Cha, S.-S., Kim, M.-S., Choi, Y. H., Sung, B.-J., Shin, N. K., Shin, H.-C., Sung, Y. C., & Oh, B.-H. (1999) · Immunity · doi:10.1016/s1074-7613(00)80100-4 · Cited by 158
Mariani, S. M., Matiba, B., Armandola, E. A., & Krammer, P. H. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.221 · Cited by 145
Structure-activity studies of human tumour necrosis factors
Ostade, X. V., Tavernier, J., & Fiers, W. (1994) · Protein Engineering Design and Selection · doi:10.1093/protein/7.1.5 · Cited by 73
Cited by
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationTNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Self-citationThe molecular architecture of the TNF superfamily
Bodmer, J.-L., Schneider, P., & Tschopp, J. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01995-8 · Cited by 916
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationZinc coordination sphere in biochemical zinc sites
Auld, D. S. (2001) · Biometals · doi:10.1023/a:1012976615056 · Cited by 721
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citationFrom bench to clinic with apoptosis-based therapeutic agents
Nicholson, D. W. (2000) · Nature · doi:10.1038/35037747 · Cited by 687
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Self-citationKelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Self-citationInteractions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human
Bossen, C., Ingold, K., Tardivel, A., Bodmer, J.-L., Gaide, O., Hertig, S., Ambrose, C., Tschopp, J., & Schneider, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601553200 · Cited by 443
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationAshkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Self-citationTargeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
New insights into apoptosis signaling by Apo2L/TRAIL
Gonzalvez, F., & Ashkenazi, A. (2010) · Oncogene · doi:10.1038/onc.2010.221 · Cited by 359
Self-citationThe Methionine-aromatic Motif Plays a Unique Role in Stabilizing Protein Structure
Valley, C. C., Cembran, A., Perlmutter, J. D., Lewis, A. K., Labello, N. P., Gao, J., & Sachs, J. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.374504 · Cited by 345
Yan, M., Wang, L.-C., Hymowitz, S. G., Schilbach, S., Lee, J., Goddard, A., de Vos, A. M., Gao, W.-Q., & Dixit, V. M. (2000) · Science · doi:10.1126/science.290.5491.523 · Cited by 311
Self-citationOnto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation
Cai, G., & Freeman, G. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00783.x · Cited by 301
Stenqvist, A.-C., Nagaeva, O., Baranov, V., & Mincheva-Nilsson, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301885 · Cited by 292
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Self-citationStructural principles of tumor necrosis factor superfamily signaling
Vanamee, É. S., & Faustman, D. L. (2018) · Science Signaling · doi:10.1126/scisignal.aao4910 · Cited by 280
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 272
Death receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Self-citationA novel Gln358Glu mutation in ectodysplasin A associated with X-linked dominant incisor hypodontia.
Tarpey, P., Pemberton, T. J., Stockton, D. W., Das, P., Ninis, V., Edkins, S., Andrew Futreal, P., Wooster, R., Kamath, S., Nayak, R., et al. (2007) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31567 · Cited by 51
Metadata
- Authors
- Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-01-04
- Volume
- 39
- Issue
- 4
- Pages
- 633-640
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2119500275
- Cited by
- 261
- References
- 7
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.